This market assessment aims to increase the awareness of biotechnology and pharmaceutical companies worldwide about the opportunities and potential markets that exist for low-cost and effective vaccines against enterotoxigenic Escherichia coli (ETEC). In addition, it provides donors and commercial investors with a better understanding of the potential risks, rewards, and gaps in knowledge relative to these opportunities as they consider their own investment strategies. The resulting analysis demonstrates that ETEC vaccines may represent a moderate opportunity for industry investment with an estimated annual revenue potential of more than US$600 million ten years after global launch.

Corporate author(s): PATH, BIO Ventures for Global Health

Publication date: March 2011

Region: Global

See also:

Maternal and child health > Controlling diarrheal disease

Vaccines and immunization > Diarrheal disease

For more information…

Contact: PATH Publications
Email: publications@path.org
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA